公司库 > 公司详情页

$ 26.93

+1.15(4.46%)

04-24 16:08

WAVE Life Sciences Ltd. - Ordinary Shares

Wave Life Sciences Ltd. operates as a preclinical biopharmaceutical company, which engages in the development and provision of nucleic acid therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Cambridge, MA.
最高：27.67今开：25.82成交量：56.74万股换手：1.66%
最低：25.40昨收：25.78成交额：1477.01万振幅：8.80%
52周最高：56.00量比：0.31市盈率(TTM)：亏损市净率：10.82
52周最低：22.90委比：33.33%市盈率(静)：亏损市销率：65.02
每股收益：-5.06股息：--每手股数：1总市值：9.21亿
每股净资产：2.49股息率：--最小价差：0.01总股本：3419.21万
机构持股：--Beta：0.83空头回补天数：6.03货币单位：USD
最新获投
暂无数据
最新动态
暂无数据
五力模型
财务指标
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
流动资产
2.68亿
1.18亿
1.50亿
1.74亿
2.01亿
现金及短期投资
2.41亿
1.10亿
1.43亿
1.68亿
1.97亿
短期应收账款
1,500.00万
--
--
--
--
存货
--
--
--
--
--
其他流动资产
1,124.30万
747.00万
798.50万
537.00万
383.00万
非流动资产
8,606.90万
3,246.00万
3,135.50万
2,825.20万
2,520.80万
厂房及设备净资产
3,238.40万
2,877.80万
2,733.40万
2,458.40万
2,077.50万
项目总投资及垫款
361.60万
361.20万
361.00万
360.80万
360.60万
长期应收票据
5,000.00万
--
--
--
--
无形资产
--
--
--
--
--
递延所得税资产
--
--
--
--
77.40万
其他资产
6.90万
7.00万
41.10万
6.00万
5.30万
合计总资产
3.54亿
1.50亿
1.82亿
2.02亿
2.26亿
流动负债
4,378.10万
1,629.80万
1,962.10万
1,512.20万
1,555.50万
短期债务（含部分LTD）
--
--
1.60万
70.90万
27.80万
应付账款
715.10万
801.40万
759.80万
470.50万
798.30万
应付所得税
--
--
--
--
--
其他流动负债
3,663.00万
828.40万
1,200.70万
970.80万
729.40万
非流动负债
1.63亿
1,620.00万
1,453.40万
1,323.40万
2,196.50万
长期负债
--
--
--
209.30万
219.70万
拨备风险及费用
--
--
--
--
--
递延所得税负债
--
--
--
--
--
其他负债
1.63亿
1,620.00万
1,453.40万
1,114.10万
1,976.80万
合计总负债
2.07亿
3,249.80万
3,415.50万
2,835.60万
3,752.00万
股东权益合计
1.47亿
1.18亿
1.48亿
1.74亿
1.89亿
非股权储备
--
--
--
--
--
优先股-账面价值
7.87
7.87
7.87
7.87
7.87
普通股权益（合计）
1.39亿
1.10亿
1.40亿
1.66亿
1.81亿
累计少数股东权益
--
--
--
--
--
权益总额
1.47亿
1.18亿
1.48亿
1.74亿
1.89亿
负债与股东权益合计
3.54亿
1.50亿
1.82亿
2.02亿
2.26亿
每股账面价值
4.76
3.93
5.02
5.97
6.53
每股账面价值-有形
4.76
3.93
5.02
5.97
6.53
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
营业总收入
487.90万
142.20万
167.60万
67.60万
67.60万
-营业成本
487.90万
142.20万
167.60万
67.60万
67.60万
毛利
--
--
--
--
--
-销售管理及行政费用
4,021.80万
3,602.20万
3,136.70万
2,707.30万
2,541.40万
-其他运营费用
--
--
--
--
--
计息税前利润
-3,657.30万
-3,577.50万
-3,058.00万
-2,699.20万
-2,509.40万
+非经营收入(支出)
67.90万
70.60万
17.20万
44.10万
41.90万
-非经常性支出
--
--
--
--
--
-利息支出
--
--
--
--
--
税前净利润
-3,589.40万
-3,506.90万
-3,040.80万
-2,655.10万
-2,467.50万
-所得税
--
17.20万
-19.70万
-41.60万
1.80万
+其他税后调整
0.00
0.00
0.00
0.00
0.00
+联署公司盈利权益
--
--
--
--
--
合并净利润
-3,589.40万
-3,524.10万
-3,021.10万
-2,613.50万
-2,469.30万
-少数股东权益开支
--
--
--
--
--
净利润
-3,589.40万
-3,524.10万
-3,021.10万
-2,613.50万
-2,469.30万
-优先股股息
--
--
--
--
--
一般可用收入净利润
-3,589.40万
-3,524.10万
-3,021.10万
-2,613.50万
-2,469.30万
每股基本收益
-1.23
-1.26
-1.09
-0.94
-0.92
摊薄每股收益
-1.23
-1.26
-1.09
-0.94
-0.92
息税折旧摊销前利润
-3,533.90万
-3,460.00万
-2,969.10万
-2,639.70万
-2,473.80万
单位:美元
2017-12-31
2016-12-31
2015-12-31
2014-12-31
净收益
-1.02亿
-5,540.10万
-1,920.00万
-522.90万
+折旧损耗及摊稍
215.50万
78.40万
59.40万
28.10万
+递延税及投资税减免
77.40万
-56.40万
3.60万
8.40万
+其他经营基金
1,573.40万
710.20万
411.20万
8,000.00
营运资金
-8,337.20万
-4,807.90万
-1,445.80万
-485.60万
+特别项目
--
--
--
--
+营运资金变动
-29.90万
1,620.70万
193.10万
43.00万
经营现金流
-8,367.10万
-3,187.20万
-1,252.70万
-442.60万
资本支出
-1,888.70万
-556.70万
-185.70万
-59.00万
收购所得净资产
--
--
--
--
固定资产和业务出售收入
--
4,000.00
3,000.00
33.30万
投资买卖净额
-9,000.00
-259.90万
-105.50万
--
非现金项目
0.00
0.00
0.00
0.00
投资现金流
-1,889.60万
-816.20万
-290.90万
-25.70万
发放现金股利
--
--
--
--
股本变动
9,443.60万
2,918.30万
1,163.10万
558.50万
发行/削减债务净额
-6.20万
-6.20万
-12.60万
--
其他融资基金
--
--
1.64亿
3.40万
筹资现金流
9,437.40万
2,912.10万
1.76亿
561.90万
汇率影响
40.30万
-1.40万
1.50万
-32.70万
杂项基金
--
--
--
--
现金净流动
-779.00万
-1,092.70万
1.60亿
60.90万
自由现金流
-1.03亿
-3,743.90万
-1,438.40万
-501.60万
公司高管
Christian O. Henry
Presently, Christian O. Henry occupies the position of Chairman at Wave Life Sciences Ltd. He is also on the board of Pacific Biosciences of California, Inc. Mr. Henry previously occupied the position of Vice President-Finance & Controller at Nektar Therapeutics, Chief Commercial Officer & Executive VP at Illumina, Inc., Chief Financial Officer of Tickets.com, Inc., Vice President-Finance & Controller at Affymetrix, Inc., Senior Vice President & General Manager at Genomic Solutions, Inc. and General Accounting Manager at Sugen LLC. Christian O. Henry received an undergraduate degree from the University of California San Diego and an MBA from the University of California, Irvine.
Roberto Guerciolini
Dr. Roberto Guerciolini, MD MBA, is a Member at American Board of Clinical Pharmacology, Inc. and Senior Vice President & Head-Early Development at Wave Life Sciences Ltd. Dr. Guerciolini was previously employed as SVP-Pharmaceutical Development by Dicerna Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President by Sirna Therapeutics, Inc., a Principal by Hoffmann-La Roche, Inc., a Principal by Schering-Plough Corp., and Senior Director-Clinical Pharmacology by Millennium Pharmaceuticals, Inc. He received his MBA from the University of California, Berkeley and a doctorate degree from Università degli Studi di Perugia.
Clare M. Carmichael
Currently, Clare M. Carmichael holds the position of Chief Human Resources Officer at Wave Life Sciences Ltd. She previously was Chief Human Resources Officer & Executive VP at Alexion Pharmaceuticals, Inc., Vice President-Human Resources of Eyetech Pharmaceuticals, Inc., Head-Human Resources at Pharmacia Corp., Vice President-Global Human Resources at Schering-Plough Research Institute and Senior Vice President-Global Human Resources at Actavis, Inc. Ms. Carmichael received an undergraduate degree from Rider University.
Adrian Rawcliffe
Presently, Adrian Rawcliffe holds the position of CFO & Principal Accounting Officer of Adaptimmune Therapeutics Plc and Chief Financial Officer at Human Genome Sciences, Inc. He is also on the board of Morphotek, Inc. and Wave Life Sciences Ltd. In the past Mr. Rawcliffe occupied the position of Managing Partner at SR One Ltd., Chartered Accountant at Coopers & Lybrand LLP, Vice President of GlaxoSmithKline Biologicals SA and Principal at AlgoRx Pharmaceuticals, Inc. He received an undergraduate degree from the University of Durham.
Chandra Vargeese
Chandra Vargeese is Senior Vice President-Drug Discovery at Wave Life Sciences Ltd. Dr. Vargeese previously held the position of Vice President-Delivery at Sirna Therapeutics, Inc. and Associate Director-Chemistry at NeXstar Pharmaceuticals, Inc. Chandra Vargeese received a doctorate from Indian Institute of Science.
Christian O. Henry
Presently, Christian O. Henry occupies the position of Chairman at Wave Life Sciences Ltd. He is also on the board of Pacific Biosciences of California, Inc. Mr. Henry previously occupied the position of Vice President-Finance & Controller at Nektar Therapeutics, Chief Commercial Officer & Executive VP at Illumina, Inc., Chief Financial Officer of Tickets.com, Inc., Vice President-Finance & Controller at Affymetrix, Inc., Senior Vice President & General Manager at Genomic Solutions, Inc. and General Accounting Manager at Sugen LLC. Christian O. Henry received an undergraduate degree from the University of California San Diego and an MBA from the University of California, Irvine.
Roberto Guerciolini
Dr. Roberto Guerciolini, MD MBA, is a Member at American Board of Clinical Pharmacology, Inc. and Senior Vice President & Head-Early Development at Wave Life Sciences Ltd. Dr. Guerciolini was previously employed as SVP-Pharmaceutical Development by Dicerna Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President by Sirna Therapeutics, Inc., a Principal by Hoffmann-La Roche, Inc., a Principal by Schering-Plough Corp., and Senior Director-Clinical Pharmacology by Millennium Pharmaceuticals, Inc. He received his MBA from the University of California, Berkeley and a doctorate degree from Università degli Studi di Perugia.
Clare M. Carmichael
Currently, Clare M. Carmichael holds the position of Chief Human Resources Officer at Wave Life Sciences Ltd. She previously was Chief Human Resources Officer & Executive VP at Alexion Pharmaceuticals, Inc., Vice President-Human Resources of Eyetech Pharmaceuticals, Inc., Head-Human Resources at Pharmacia Corp., Vice President-Global Human Resources at Schering-Plough Research Institute and Senior Vice President-Global Human Resources at Actavis, Inc. Ms. Carmichael received an undergraduate degree from Rider University.
Adrian Rawcliffe
Presently, Adrian Rawcliffe holds the position of CFO & Principal Accounting Officer of Adaptimmune Therapeutics Plc and Chief Financial Officer at Human Genome Sciences, Inc. He is also on the board of Morphotek, Inc. and Wave Life Sciences Ltd. In the past Mr. Rawcliffe occupied the position of Managing Partner at SR One Ltd., Chartered Accountant at Coopers & Lybrand LLP, Vice President of GlaxoSmithKline Biologicals SA and Principal at AlgoRx Pharmaceuticals, Inc. He received an undergraduate degree from the University of Durham.
Chandra Vargeese
Chandra Vargeese is Senior Vice President-Drug Discovery at Wave Life Sciences Ltd. Dr. Vargeese previously held the position of Vice President-Delivery at Sirna Therapeutics, Inc. and Associate Director-Chemistry at NeXstar Pharmaceuticals, Inc. Chandra Vargeese received a doctorate from Indian Institute of Science.
高管交易状态
交易日期 交易人 职位 类型 交易份额 价格
2018-05-31
Francis (Christopher John)
Officer
Sell
24496
48.00
2018-05-31
Francis (Christopher John)
Officer
Sell
24496
48.00
2018-05-31
Francis (Christopher John)
Officer
Buy
24496
2.48
2018-05-31
Francis (Christopher John)
Officer
Buy
24496
2.48
2018-05-29
Francis (Christopher John)
Officer
Sell
24496
45.50
2018-05-29
Francis (Christopher John)
Officer
Buy
24496
2.48
2018-05-29
Francis (Christopher John)
Officer
Sell
24496
45.50
2018-05-29
Francis (Christopher John)
Officer
Buy
24496
2.48
2018-05-29
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
20250
2.48
2018-05-29
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
20250
45.00
2018-05-29
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
20250
2.48
2018-05-29
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
20250
45.00
2018-05-28
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
3145
2.48
2018-05-28
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
3145
45.00
2018-05-28
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
3145
2.48
2018-05-28
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
3145
45.00
2018-05-24
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
8316
45.00
2018-05-24
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
8316
2.48
2018-05-24
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
8316
45.00
2018-05-24
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
8316
2.48
2018-05-01
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
18289
2.48
2018-05-01
Bolno (Paul B. M.D.)
Chief Executive Officer
Buy
18289
2.48
2018-05-01
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
18289
45.00
2018-05-01
Bolno (Paul B. M.D.)
Chief Executive Officer
Sell
18289
45.00
2018-02-19
Francis (Christopher John)
Officer
Buy
11504
2.48
2018-02-19
Francis (Christopher John)
Officer
Sell
11504
55.95
2018-02-19
Francis (Christopher John)
Officer
Buy
11504
2.48
2018-02-19
Francis (Christopher John)
Officer
Sell
11504
55.95
2018-02-15
Francis (Christopher John)
Officer
Sell
9412
55.00
2018-02-15
Regnante (Keith C)
Chief Financial Officer
Sell
316
51.85
查看更多
持股状况
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Point72 Asset Management, L.P.
350000
--
307700
727.42%
2018-06-30
BB Biotech AG
1137885
--
241789
26.98%
2018-06-30
HHG PLC
1518758
--
160545
11.82%
2018-06-30
Boxer Capital LLC
1590600
--
240600
17.82%
2018-06-30
T. Rowe Price Associates, Inc.
1661851
--
-76234
-4.39%
2018-06-30
Redmile Group, LLC
2244507
--
6900
0.31%
2018-06-30
Kagoshima Development Co Ltd
2494865
--
-300000
-10.73%
2018-01-31
Shin Nippon Biomedical Laboratories Ltd
1984130
--
--
--
2018-03-19
RA Capital Management, LLC
7512049
--
--
--
2018-06-30
Bellevue Asset Management AG
1137885
--
241789
26.98%
2018-06-30
Fidelity Management and Research Company
1036878
--
59879
6.13%
2018-06-30
Janus Capital Management LLC
770089
--
72664
10.42%
2018-06-30
Wells Capital Management Inc.
353618
--
353618
--
2018-06-30
EcoR1 Capital, LLC
412871
--
-1046201
-71.70%
2018-06-30
New Leaf Venture Partners, L.L.C.
433429
--
-24830
-5.42%
2018-06-30
Arrowpoint Asset Management, LLC
454999
--
66280
17.05%
2018-06-30
BlackRock Institutional Trust Company NA
463266
--
108195
30.47%
2018-06-30
Bridger Management LLC
562615
--
43180
8.31%
2018-06-30
Teva Pharmaceutical Industries Ltd
1384700
--
-490300
-26.15%
2017-08-30
BlackRock Inc
738389
--
216464
41.47%
2018-06-30
State Street Corp
341848
--
73340
27.31%
2018-06-30
Perceptive Advisors LLC
462798
--
-200000
-30.18%
2018-03-31
Eventide Asset Management, LLC
378000
--
-55500
-12.80%
2018-03-31
Great Point Partners LLC
331085
1.19%
331085
--
2017-12-31
Vanguard Group Inc
261770
0.94%
33899
14.88%
2017-12-31
Deerfield Management Co
314674
1.13%
-265326
-45.75%
2017-12-31
Foresite Capital Management LLC
676128
2.88%
-734561
-52.07%
2016-12-31
Janus Capital International Ltd
168837
0.61%
3955
2.40%
2017-12-31
Clough Capital Partners, LP
159403
0.57%
-49300
-23.62%
2017-12-31
Cormorant Asset Management, LLC
202079
0.73%
--
--
2017-09-30
Northern Trust Investments N A
157312
0.57%
-8482
-5.12%
2017-09-30
BlackRock Fund Advisors
525112
1.75%
-2383
-0.45%
2017-12-28
Sabby Management LLC
141700
0.51%
141700
--
2017-06-30
Geode Capital Management, LLC
132984
0.48%
56506
73.89%
2017-06-30
BlackRock Advisors LLC
27959
0.12%
-1163
-3.99%
2016-09-30
TIAA-CREF Investment Management LLC
28000
0.12%
--
--
2016-09-30
Jennison Associates LLC
75435
0.32%
75435
--
2016-09-30
Pfizer Inc
1875000
8.70%
1875000
--
2016-05-05
Masaharu Tanaka
3152440
11.00%
50439040
0.20%
1999-11-30
Ken Takanashi
1859130
11.00%
29746080
0.10%
1999-11-30
Foresite Capital Fund III, L.P.
1333725
11.00%
21339600
0.10%
1999-11-30
FMR LLC
1212477
11.00%
19399632
0.10%
1999-11-30
Peter Kolchinsky, Ph.D.
5213651
11.00%
83418416
0.20%
1999-11-30
持有者 持有份额 持股比例 份额变化 变化率 报告日期
SPDR
44917
0.15%
--
--
2018-09-13
T. Rowe Price Health Sciences
279200
0.95%
-5698
-2.00%
2018-06-30
Wells Fargo Discovery Admin
238300
0.81%
--
--
2018-07-31
Meridian Small Cap Growth Investor
244733
0.84%
35248
16.83%
2018-06-30
T. Rowe Price Instl Small-Cap Stock
239833
0.82%
--
--
2018-06-30
iShares Russell 2000 Growth
170586
0.58%
-164
-0.10%
2018-09-12
T. Rowe Price New Horizons
215378
0.74%
215378
--
2018-06-30
Vanguard Extended Market Idx Inv
199436
0.68%
7348
3.83%
2018-07-31
PowerShares Dynamic Biotech & Genome ETF
150628
0.51%
--
--
2018-09-13
Eventide Healthcare & Life Sciences A
170400
0.58%
-51600
-23.24%
2018-06-30
Eventide Gilead N
156000
0.53%
--
--
2018-06-30
iShares US Pharmaceuticals
90192
0.30%
--
--
2018-09-12
Fidelity
81200
0.28%
--
--
2018-07-31
Fidelity Spartan
72154
0.25%
--
--
2018-07-31
T. Rowe Price QM US Small-Cap Growth Eq
73047
0.25%
1200
1.67%
2018-06-30
AST Small-Cap Growth
66272
0.23%
--
--
2018-07-31
Janus Venture D
287582
0.98%
--
--
2018-06-30
Janus Global Life Sciences D
482507
1.65%
72664
17.73%
2018-06-30
T. Rowe Price Small-Cap Stock
499957
1.71%
-3000
-0.60%
2018-06-30
Schwab US Small-Cap ETF
42039
0.19%
--
--
2018-08-30
Fidelity Advisor
246366
0.84%
--
--
2018-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending
43301
0.15%
14446
50.06%
2018-06-30
iShares Micro-Cap
29012
0.10%
--
--
2018-06-14
Driehaus Micro Cap Growth
27319
0.10%
27319
--
2018-02-28
Active Port
27018
0.10%
27018
--
2018-02-28
Vanguard Health Care ETF
25109
0.09%
72
0.29%
2018-02-28
SEI Small Cap Growth A (SIMT)
24842
0.09%
8856
55.40%
2018-02-28
SEI Small Cap II A (SIIT)
24319
0.09%
14643
151.33%
2018-02-28
CREF Stock R1
20761
0.07%
-318
-1.51%
2017-11-30
BlackRock Russell 2500
9671
0.04%
2808
40.92%
2016-12-31
BlackRock Russell 2000
9771
0.04%
559
6.07%
2016-12-31
Schwab Small Cap Index
11500
0.05%
--
--
2016-12-31
AXA 2000 Managed Volatility K
10294
0.04%
--
--
2016-11-30
iShares Russell 2000 Value
13207
0.06%
-54
-0.41%
2017-02-07